Industry News

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Spine Innovation Completes First Surgery with LOGIC Titanium Expandable Interbody System: Reported by OrthoSpineNews, Spine Innovation announced the successful completion of the first clinical procedure with its LOGIC Titanium Expandable Interbody System featuring Sites Medical OsteoSync Ti porous lattice, performed by Robert Eastlack, MD at Scripps Green Hospital.
• Synergy Spine Solutions Reports Four-Year Real-World Outcomes for Synergy Disc at NASS 2026: Reported by OrthoSpineNews, Synergy Spine Solutions presented multicenter PERFORM study findings from 120 patients at the North American Spine Society 2026 Annual Meeting, demonstrating 100% device survival through up to four years, marked pain and disability score reductions at two years, and zero device-related adverse events.
• FDA and CMS RAPID Pathway Fast-Tracks Medicare Coverage for Breakthrough Orthopaedic Devices: Reported by BONEZONE, the joint Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway aligns FDA premarket authorization and CMS coverage determinations into a front-loaded process, proposing national coverage determinations on the day of FDA clearance with final determinations within 60 to 90 days.
• Encore Medical Receives 510(k) Clearance for AltiVate Reverse Glenosphere with RAVN Technology: Encore Medical L.P. received FDA 510(k) clearance (K263086) for the AltiVate Reverse Glenosphere with RAVN Technology, indicated for primary, revision, or secondary reverse total shoulder arthroplasty.
• Paragon 28 Obtains 510(k) Clearance for APEX 3D S Diamond Tibia: Paragon 28, Inc. secured FDA 510(k) clearance (K261120) for the APEX 3D S Diamond Tibia component, indicated for primary or revision total ankle arthroplasty in patients with end-stage arthritis.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Orthobiologics

Spine Innovation, LLC: Spine Innovation Announces First Surgery with LOGIC Titanium Expandable Interbody System

• Summary: Spine Innovation, LLC announced the successful completion of the first surgical procedure utilizing the LOGIC Titanium Implant System (LOGIC Ti). The procedure was performed on October 14, 2026 by orthopaedic spine surgeon Robert Eastlack, MD at Scripps Green Hospital in La Jolla, California for transforaminal lumbar fusion. The patented LOGIC Ti expandable interbody device transforms from a less invasive insertion footprint into a large, stable expanded implant with an 18 x 26 mm footprint designed to span the vertebral body, restoring disc height and sagittal balance while resisting subsidence and expulsion. The system incorporates OsteoSync Ti, a patented commercially pure titanium lattice material from Sites Medical that has been implanted in more than 350,000 orthopaedic and spine patients since 2014. Founded in 2013 in collaboration with Scripps Health surgeon inventors, Spine Innovation previously utilized the LOGIC design manufactured from polyether ether ketone (PEEK).
• Key Details:
  • Device/System Name: LOGIC Titanium Expandable Interbody System (LOGIC Ti)
  • Status: First Surgical Procedure Completed (October 14, 2026)
  • Clinical Significance: Enables transforaminal lumbar fusion through a less invasive insertion approach that expands into an 18 x 26 mm footprint, optimizing volume for bony fusion while utilizing a clinically established commercially pure titanium porous lattice to facilitate biological fixation.
• Original Source: OrthoSpineNews

Clinical & Registry Evidence

Synergy Spine Solutions: Synergy Spine Solutions Announces PERFORM International Real-World Study Results for Synergy Disc at NASS 2026

• Summary: At the North American Spine Society (NASS) 2026 Annual Meeting in San Antonio, Synergy Spine Solutions announced clinical results from PERFORM, an ongoing international, multicenter, open-label, pragmatic real-world study evaluating the Synergy Disc. The study evaluated 120 patients across five clinical sites in the United Kingdom, European Union, and Australia receiving single-level cervical disc replacement, with 30% also undergoing anterior cervical discectomy and fusion (ACDF) during the same procedure. Patients demonstrated sustained improvements in neck pain and functional disability: mean Neck Disability Index (NDI) scores dropped from 43.4 prior to surgery to 16.4 at six weeks and 7.8 at two years, remaining low at three years. Mean neck pain scores decreased from 5.8 at baseline to 0.8 at two years. Kaplan-Meier survivorship analysis demonstrated 100% device survival through up to four years, with no device-related adverse events, explants, or supplemental fixation reported.
• Key Details:
  • Device/System Name: Synergy Disc Cervical Disc Replacement
  • Status: Multicenter Real-World Clinical Study Results Presented at NASS 2026
  • Clinical Significance: Confirms four-year real-world durability and safety for motion-preserving cervical arthroplasty designed to address sagittal alignment, demonstrating marked pain relief and zero device-related revisions across international centers.
• Original Source: OrthoSpineNews

Corporate, M&A & Regulatory

FDA & CMS: RAPID Pathway Fast-Tracks Medicare Coverage and Reimbursement for Orthopaedic Breakthrough Devices

• Summary: The Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) have established the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway to resolve historic delays between premarket device authorization and Medicare reimbursement. Historically, FDA safety and effectiveness evaluations and CMS reasonable and necessary coverage determinations were conducted independently, forcing orthopaedic manufacturers to navigate years of sequential, unpredictable milestones or repeat multi-year investigational device exemption (IDE) studies. Under the RAPID pathway, CMS coverage considerations are integrated directly into early IDE study design. Qualifying technologies must hold Breakthrough Device designation, address unmet clinical needs of Medicare beneficiaries, and evaluate agreed-upon clinical health outcomes. Class II technologies must participate in the FDA Total Product Life Cycle Advisory Program (TAP) under a planned De Novo request, while Class III devices preparing Premarket Approval (PMA) applications qualify regardless of TAP participation. Under RAPID, CMS issues a proposed national coverage determination (NCD) on the same day FDA market authorization is granted, followed by a final NCD within approximately 60 days for Class II devices and 90 days for Class III devices.
• Key Details:
  • Device/System Name: Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway
  • Status: Joint Regulatory and Reimbursement Harmonization Program Launched
  • Clinical Significance: Eliminates regulatory and reimbursement lag for novel orthopaedic implants by front-loading CMS coverage requirements into pivotal IDE trials, guaranteeing proposed Medicare coverage concurrent with FDA clearance and final coverage within 60 to 90 days.
• Original Source: BONEZONE

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES: ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2 to 4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.